Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2012 / Article
Special Issue

Antioxidant Therapies for Neurodegenerative Diseases: Mechanisms, Current Trends and Perspectives

View this Special Issue

Research Article | Open Access

Volume 2012 |Article ID 843649 | https://doi.org/10.1155/2012/843649

Sergio Rosales-Corral, Dario Acuna-Castroviejo, Dun Xian Tan, Gabriela López-Armas, José Cruz-Ramos, Rubén Munoz, Valery G. Melnikov, Lucien C. Manchester, Russel J. Reiter, "Accumulation of Exogenous Amyloid-Beta Peptide in Hippocampal Mitochondria Causes Their Dysfunction: A Protective Role for Melatonin", Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 843649, 15 pages, 2012. https://doi.org/10.1155/2012/843649

Accumulation of Exogenous Amyloid-Beta Peptide in Hippocampal Mitochondria Causes Their Dysfunction: A Protective Role for Melatonin

Academic Editor: Daniel Pens Gelain
Received14 Oct 2011
Accepted12 Jan 2012
Published13 May 2012


Amyloid-beta (Aβ) pathology is related to mitochondrial dysfunction accompanied by energy reduction and an elevated production of reactive oxygen species (ROS). Monomers and oligomers of Aβ have been found inside mitochondria where they accumulate in a time-dependent manner as demonstrated in transgenic mice and in Alzheimer’s disease (AD) brain. We hypothesize that the internalization of extracellular Aβ aggregates is the major cause of mitochondrial damage and here we report that following the injection of fibrillar Aβ into the hippocampus, there is severe axonal damage which is accompanied by the entrance of Aβ into the cell. Thereafter, Aβ appears in mitochondria where it is linked to alterations in the ionic gradient across the inner mitochondrial membrane. This effect is accompanied by disruption of subcellular structure, oxidative stress, and a significant reduction in both the respiratory control ratio and in the hydrolytic activity of ATPase. Orally administrated melatonin reduced oxidative stress, improved the mitochondrial respiratory control ratio, and ameliorated the energy imbalance.

1. Introduction

The intracellular accumulation of highly amyloidogenic 1–42 residue amyloid-beta peptide ( ) may result from, (a) decreased Aβ degradation due to disruption of the ubiquitin-proteasome system, (b) increased intracellular generation of Aβ, or (c) increased uptake of Aβ from an external source [1, 2]. The internalization of peptide by primary neurons is related to a lipid raft-mediated endocytosis [2]. These lipid rafts are dynamic assemblies of proteins and lipids floating freely within the liquid-disordered bilayer of cellular membranes where cholesterol and sphingomyelin play key roles [3]. Reciprocally, cholesterol and sphingomyelin metabolism are strongly related to Aβ [4]. In fact, there are clues indicating that Aβ levels change in response to blood cholesterol content, while the clinical progression of Alzheimer’s disease (AD) is commonly associated to hypercholesterolemia and high cholesterol levels in the brain [5, 6].

Another factor gaining more relevance as a mechanism of neuronal damage is oxidative stress, which is a hallmark feature of Aβ-induced brain damage in AD [7], AD transgenic mice [8], as well as in in vitro and other in vivo models of this neurodegenerative condition [9, 10]. Mitochondrial dysfunction and associated oxidant stress have been linked to numerous complex diseases and aging [11, 12], such association has been largely established by in vitro determination of mitochondrial free radicals overproduction. Membrane-associated oxidative stress in turn has been linked to lipid alterations [13], and the exposure of hippocampal neurons to Aβ, in vitro, induces oxidative damage to membranes, accompanied by accumulation of sphingomyelin-derived ceramide species and cholesterol [14]. In fact, by preventing the accumulation of ceramides and cholesterol it is possible to protect neurons from death induced by Aβ; this is achieved with an antioxidant like α-tocopherol or by depleting hippocampal neurons of its sphingomyelin content with an inhibitor of serine palmitoyltransferase, the rate-limiting step in sphingolipid synthesis [15]. Focal demyelination of the cortical grey matter as well as of dystrophic neurites has been observed in AD patients and transgenic mice associated to Aβ plaque core [16]. Thus, it is possible that the breakdown of myelin promotes the buildup of toxic Aβ fibrils, which eventually accumulate in the brain [17].

There is evidence, on the other hand, that the amyloid precursor protein (APP) and Aβ accumulate in mitochondrial membranes, as observed in postmortem AD or in transgenic mice brain sections [1820]. Aβ extracellularly applied to human neuroblastoma SH-SY5Y cells was found to be internalized and be taken up by mitochondria by using the transporter outer membrane (TOM) [21]. Most of the imported appeared associated to the inner membrane and only a small fraction was localized to the matrix.

We hypothesized that due to its amphipathic nature [22], its physicochemical composition [23], and being aided by oxidative stress [10, 24], Aβ paves its own pathway from extracellular space to mitochondria where it disrupts membrane fluidity and causes energetic dysfunction. This mechanism of membrane permeabilization induced by Aβ and its own internalization might be the major cause of mitochondrial dysfunction.

Since oxidative stress is considered a key factor in these pathogenic mechanisms, melatonin should reduce the dysfunctional manifestations of Aβ uptake [25]. Melatonin is a proven antioxidant [26, 27], especially in the brain where it reduces molecular damage as demonstrated in animal models of AD [28, 29], as well as in other experimental models of neurodegeneration [3033]. There are two important clues regarding the role of melatonin in mitochondria rescue, (1) melatonin penetrates mitochondria where it scavenges free radicals [34, 35], (2) melatonin directly inhibits mitochondrial permeability transition pore (MtPTP) [36].

To further document these potential protective effects of melatonin, we worked in vivo by injecting fibrillar directly into hippocampal CA1 pyramidal neurons layer. Aged Wistar rats used in these experiments had no other condition or genetic predisposition to form plaques or other AD features.

2. Results

2.1. Axonal Damage in fAβ Injected Rats

The most striking abnormal change was the intramural accumulation, adhesion, and formation of Aβ aggregates in the myelinated axons. Thus, Aβ invaded the concentric multilamellar myelin sheath of the axon (oligodendrocyte cytoplasm). These Aβ aggregates caused dissection and disruption of myelin layers with mural vacuolization, forming onion bulb-like protuberances as found in chronic neuropathies [37]. In some cases, all layers were disrupted and positive Aβ-immunoreactivity extending from the interstitium to the axonal lumen was observed (Figure 1). Within the onion bulb-like protuberances, Aβ appeared to form aggregates; once inside the axons and mitochondria, the Aβ aggregates were disintegrated, adopting a granular appearance.

2.2. Cholesterol-Enriched Diet in Aβ-Injected Rats Is Related to a Significant Increase in Mitochondrial Membrane Damage

Animals fed with regular Laboratory Rodent Diet showed a normal cholesterol level in blood. When these animals were intracerebrally injected with Aβ showed not only significantly less degree of mitochondrial structural damage as compared to Aβ-injected but also hypercholesterolemic animals due to a cholesterol-enriched diet, as observed by electron microscopy (Figure 2).

2.3. Intracerebrally Injected fA Causes Extracellular Aggregates, Axonal Degeneration, and Accumulates in Mitochondria

Thirty-six hours following the intracerebral injection of f , brain tissue was obtained and subjected to conventional and transmission electron microscopic examination. Using a polyclonal antibody against Aβ for immunohistochemistry, extracellular deposits of this peptide accompanied by an intense microglial response (data not shown) were revealed, as expected (Figure 3 ). 70–90 nm ultrathin brain sections were incubated with the same anti-Aβ primary antibody, followed by incubation with a gold-labeled secondary antibody. The observation by electron microscopy revealed Aβ immunoreactivity inside mitochondria (Figure 3 ), accompanied by important swelling, rupture of the outer membrane and cristae dissolution (Figures 3 and 3 ). Aβ was found localized to the cristae of the inner membrane of mitochondria. Both in H2O2- and in fAβ-injected brains significant ultrastructural alterations were observed. H2O2 was chosen as a positive control of oxidative stress, because of its well-known pathogenic relationship with Aβ (reviewed in [38]). The most prominent change was the peripheral vacuolization of the cristae, as shown in Figure 3. Vacuolization in mitochondria was accompanied by electrodense Aβ-immunoreactivity with inclusions being grouped and bound to the membranes, particularly to the inner cristae membranes. Rupture of the membranes resulted in discontinuity and formation of gaps. Mitochondria looked swollen with disorganized membrane structures and the cristae were lost. In some localized areas, the intermembranous space was absent and the mitochondrion appeared like an irregularly enlarged, single-membrane sac (Figure 3 ).

2.4. The Incorporation of Intracerebrally Injected Aβ into Mitochondria Is Related to Mitochondrial Free Radical Overproduction

Brain sections were obtained from each group to determine mitochondrial mass density by using Mitotracker Green FM, a selective fluorescent dye whose mitochondria localization is independent of the membrane potential. Mitochondria from PBS-injected brains showed uniform box-like shapes regularly distributed and ranging in size from 318 to 1832 nm (mean  nm) with an average integrated optical density (IOD) of (Figures 4(a) and 4(b)). In Aβ-injected brains, mitochondria was found to form perinuclear clusters with a size ranging from 529 to 7400 nm (mean  nm, IOD = ) (Figures 4(c) and 4(d)). Similar clusters were observed in H2O2-injected rats ( ), and they reached a size up to 23 μm (Figures 4(e) and 4(f)).

In order to correlate the presence of Aβ within mitochondria and overproduction of free radicals by mitochondria, 36 hours following the application of and 2 hours before obtaining the tissue sample, CM-H2XRos, a chloromethyl derivative of dihydro-X-rosamine, was intraperitoneally injected; CM-H2XRos is a potential-dependent probe which evaluates the direct production of mitochondrial reactive oxygen species (ROS) in cells. Red CM-H2XRos dye has the ability of diffusing into living cells, labeling only actively respiring mitochondria [39] and it is well retained after fixation. Once located within cells, the reduced CM-H2XRos is oxidized by ROS to a fluorescent mitochondrion-sensitive probe and sequestered in this organelle; thus, its oxidation is useful to detect both ROS (predominantly superoxide anion, ) and possibly reactive nitrogen species (nitric oxide, NO, and peroxynitrite, ONOO). By comparing the IOD of randomly selected regions of equal size within a single optical section, multiplied by the number of CM-H2XRos-stained mitochondria, the overproduction of ROS for each group was estimated. Thus, fAβ-injected brains showed a significant ROS overproduction, as expected (graph in Figure 4).

2.5. Melatonin Significantly Reduces ROS Overproduction

Orally administered (20 mg/kg/day added to the drinking water), melatonin reached  pg/mL in serum between 01:00 and 02:00 h, which was 84% higher than controls (data not shown). At this dose, melatonin reduced significantly mitochondrial ROS overproduction, as graphically represented in Figure 5. Thus, IOD levels by mitochondrial CM-H2XRos in -injected brains diminished 35% in rats taking melatonin in the drinking water, whereas in H2O2 intracerebrally injected rats, melatonin treatment reduced an average of ROS levels by 69% as compared with H2O2 intracerebrally injected rats without melatonin treatment (Figure 5).

Finally, by obtaining the quotient between ROS, estimated by CM-H2XRos, and mitochondrial mass, estimated by Mitotracker green caption, the apparently greater ability of fA to cause oxidative damage with respect to H2O2 (graph in Figure 4), was reduced to its basal value (Figure 5). The ability of melatonin to reduce free radicals was significant in both experimental groups.

2.6. Amyloid-Beta Depresses Both the Respiratory Control Ratio and the ATPase Activity

36 hours following the intracerebral injection of , we found Aβ positive immunoreactivity in mitochondria, which was closely associated to mitochondrial damage and ROS overproduction, as described above. Mitochondria were then isolated in order to examine a possible correlation between the mentioned findings with functional indicators, such as the mitochondrial respiratory control ratio (RCR) and the hydrolysis activity of F1Fo-ATPase. The former measures mitochondria ability to idle at a low rate yet respond to ADP by making ATP at a high rate [40] in such a manner that is feasible to infer the leaking of electron transfer without concomitant phosphorylation, or how much ATP-synthase is partially uncoupled from respiration; the latter, as a measure of the capacity to maintain an inner-membrane potential by coupling the energy of the electrochemical proton gradient with ATP synthesis [41]. A significant difference was obtained comparing PBS-injected ( ) and fAβ groups ( ) ( ). This difference was significantly reduced when fAβ-injected animals ingested melatonin in the drinking water (fAβ fAβ Mel, ) (Figure 6).

H2O2-injected brains, used as positive controls, showed a more significant reduction in RCR ( ), and also responded to melatonin treatment (Figures 8 and 9).

Interestingly, both fAβ and H2O2 reduced ATPase hydrolytic activity but, contrary to the RCR response, melatonin did not ameliorate this parameter (fAβ = fAβ + Mel) (Figure 7).

In general, the more extensive oxidative damage was related to the lower the respiratory control ratio and the lower the ATPase hydrolytic activity (Figure 8).

2.7. There Is a Direct Correlation between Oxidative Stress-Induced Low Membrane Fluidity and a Low RCR

After establishing a link between the presence of Aβ in mitochondrion and functional disturbances in this organelle, we searched for changes in membrane fluidity. This parameter correlates with the degree of altered membrane lipid composition and it is a well-known pathogenic factor directly affecting the energetic coupling of Ca2+ pumping, with the consequent energetic failure. We found indeed, that following the intracerebral injection of fAβ and its appearance inside mitochondria, a significant reduction in membrane fluidity was evident as compared to control Ie/Im fluorescence values (fAβ versus PBS-injected controls , ). Brains of animals receiving melatonin treatment showed a significant recovery (fAβ versus fAβ Mel , ) (Figure 9).

3. Discussion

Considerable experimental data favor the hypothesis that amyloid deposition in the brain is one of the etiological factors contributing to AD dementia [43] and the hypothesis of the “intracellular cascade of Aβ” has gained preponderance [18]. It has been demonstrated that uncouples the mitochondrial respiratory chain and this plays a key role in Alzheimer’s pathology [44]. Structurally, Aβ induces swelling of isolated mitochondria [45, 46] and functionally decreases ATP synthesis and the activity of various mitochondrial enzymes, as demonstrated in vivo [47] and in vitro in cultured neuronal cells or in astrocytes exposed to the peptide [45, 47, 48]. Thus, Aβ-induced mitochondrial damage may be an extension of the amyloid cascade hypothesis, which 20 years ago suggested that the altered metabolism of APP was the initiating event in AD pathogenesis, subsequently leading to the aggregation of Aβ, specifically [43, 49]. Later, different neurotoxic mechanisms for Aβ were proposed, including disruption of mitochondrial function via binding of the Aβ-binding alcohol dehydrogenase (ABAD) protein [19], or formation of ion channels allowing calcium uptake which induces neuritic abnormalities in a dose- and time-dependent fashion [50], or the opening of the mitochondrial permeability transition pore coupled to inhibition of respiratory complexes [51, 52].

A common underlying factor is the overactivation of microglia with the consequent overexpression of proinflammatory cytokines and a significant increase in ROS, which always prevails [5356]. ROS, in turn, may come from an innate immune response promoted by damaging signals [55, 57] or they may come from the damaged mitochondria [58]. This latter implies a pathological vicious cycle, where mitochondrial dysfunction and ROS leakage from the respiratory chain feed each other. However, there is a pertinent question, is the mitochondrial impairment a consequence of intraneuronal deposits of endogenous oligomeric species of Aβ? Or are the extracellular deposits of fAβ capable of reaching mitochondria, causing their deterioration before the appearance of plaques?

APP has been localized to the trans-Golgi network, endoplasmic reticulum (ER), and endosomal, lysosomal, and mitochondrial membranes. Thus, the liberation of Aβ and formation of intracellular accumulations could potentially occur wherever APP and the β- and γ-secretases are localized, which is particularly true when APP is overexpressed (reviewed in [59]); this was not the case for the animals used in the current experimentation. The data presented here, obtained from aged Wistar rat brains, demonstrate that mitochondria undergo major structural and physiological changes following the intracerebral injection of , which in turn led to the formation of extracellular deposits which eventually appeared in mitochondria.

Mitochondrial genes seem to be activated before plaque formation, in addition to an increase in H2O2 content, accompanied by a decrease in cytochrome oxidase activity, as demonstrated in young Tg2576 mice prior to the appearance of Aβ plaques [20]. It is not clear whether a soluble, intramitochondrially produced Aβ could cause impairment of the electron transport chain since, according to the theoretical disposition of APP within the mitochondrial membrane [60], Aβ would have to be imported from outside the mitochondria, from the cytosol. This phenomenon has been revealed and involves the translocase of the outer membrane (TOM) and the translocase of the inner membrane (TIM), as shown in human cortical brain tissue specimens by Hansson Petersen et al. [21].

However, Aβ has the ability by itself to permeabilize membranes. Without discarding that Aβ from the cytosol may invade mitochondria, it is worth to consider the huge amounts of extracellular Aβ, forming plaques outside the neurons, even visible to conventional light microscopy. Aβ peptides are amphipathic molecules, containing a hydrophilic N-terminal stretch (residues 1–28) and a hydrophobic C-terminal domain (residues 29–40/42) partially spanning the APP transmembrane domain. In solution, Aβ peptides display a substantially unfolded conformation with reduced content of secondary structure; however, the latter increases considerably in phospholipid vesicles particularly when enriched in cholesterol and gangliosides [61, 62]. The ability of Aβ to insert into membranes depends more on the cholesterol: phospholipid ratio. By using the same experimental design as in this report, we have found important evidence on Aβ-induced alterations in the lipid content of mitochondrial membranes, in part related possibly to a direct Aβ molecular interaction and in part related to Aβ-induced oxidative stress (unpublished data). Oxidative stress, on the other hand, may induce membrane permeabilization by itself, as revealed by neutron reflectometry in lipid bilayers [63], whereas aging is related to changes in the cholesterol, sphingomyelin, and phospholipid content in membranes [61, 64, 65]. Thus, according to our hypothesis, all these factors are concentrated to facilitate Aβ entry into the cell and eventually to the mitochondria.

In fact, a preferential adsorption, internalization, and resistance to degradation of the major isoform of the Aβ peptide, , has been shown in differentiated PC12 cells. The amount of peptide internalized increases proportionally with the concentration of peptide in the medium and the amount of internalized is approximately 5-fold higher than the amount of [66].

Aβ, extracellularly applied to human neuroblastoma SH-SY5Y cells, was demonstrated to be internalized and taken up by mitochondria [21]. In other experiments in vivo, fluorescence in isothiocyanate- (FITC-) labeled introduced via tail vein injection into mice with a blood brain barrier (BBB) rendered permeable by treatment with pertussis toxin, readily crossed the permeabilized BBB and 48 hours later -positive neurons were widespread [67]. These experiments demonstrate the possibility that extracellular Aβ, even exogenous , may be the source of the intraneuronal Aβ. Once inside the neurons, Aβ is responsible for mitochondrial damages, as we demonstrated. We have shown in healthy rat brain that following the intracerebral injection of , this peptide accumulates in plaques outside of the cells. There was not another preexisting pathological condition or predisposition, and experiments have been carried out under in vivo conditions. The extracellular accumulation of coincided with axonal degeneration and positive Aβ immunoreactivity within mitochondria, accompanied by ultrastructural alterations consistent with mitochondrial dysfunction. All of this also coincide with Saavedra et al. [2] who found that extracellular Aβ contributes to the intracellular pool of Aβ and its internalization is not dependent of ApoE, but it is a lipid raft-mediated mechanism. Additionally, Aβ was shown to be more efficiently internalized by axons than by cell bodies.

We found, as mentioned before, axonal degenerative changes with elevated Aβ immunoreactivity (Figure 1). It is possible that this axonal degeneration could be the origin of demyelination and a pathway to permit the entry of Aβ into the neurons via retrograde transport. Previous reports have revealed increased quantities of Aβ and in AD white matter accompanied by significant decreases in the amounts of myelin basic protein, myelin proteolipid protein, and 2′,3′-cyclic nucleotide 3′-phosphodiesterase. These observations suggest that extensive white matter axonal demyelination underlies Alzheimer’s pathology, resulting in loss of capacitance and serious disturbances in nerve conduction, severely damaging brain function [68]. A new hypothesis suggests that myelin breakdown in the late-myelinating brain regions releases iron, which promotes the development of the toxic amyloid oligomers and plaques, which in turn destroy more myelin [69, 70] (Figure 1). It is worth mentioning that iron is strongly related to oxidative stress and oxidative stress is a key protagonist in neurodegenerative diseases [8, 10, 15, 24, 71, 72]. Additionally, we have also found a significant Aβ-induced rearrangement in membrane cholesterol and fatty acid composition both in cytoplasmic membranes and in mitochondrial membranes (data not shown), which culminate with a significant alteration in membrane fluidity (Figure 9).

It is well known that high levels of circulating cholesterol does not mean high cholesterol concentrations in brain tissue, essentially because cholesterol in the blood does not cross the blood brain barrier (BBB). However, hypercholesterolemia has certain association with accumulation of Aβ peptide in brain. The mechanism is not well understood, but the oxidized cholesterol metabolite 27-hydroxycholesterol likely plays a key role. Our results (Figures 2 and 9) coincide with the results from other reports [7375].

Once the internalization of Aβ and its ability to infiltrate mitochondria were documented, we proceeded to evaluate the overproduction of mitochondrial free radicals induced by the presence of Aβ, by using CM-H2XRos, a rosamine derivative well retained after fixation, which was intraperitoneally injected in vivo. This approach allowed us to examine the free radicals overproduction without changing the natural architecture of brain tissue or the interrelationship between cells. Changes in the mitochondrial mass and Aβ-linked conformational alterations were explored by using Mitotracker green, applied ex vivo on tissue brain slices.

Oxidative stress and Aβ toxicity are interdependent phenomena. In fact, the pathological effects of Aβ heavily depend on its capacity to provoke oxidative stress [42]. There are two major means by which Aβ induces oxidative stress, one is through the activation of the NADPH-oxidase probably both in neurons and in glia [76, 77], which links redox control and neuroinflammatory signaling pathways [68]. The other means by which Aβ induces oxidative stress is related to mitochondrial damage, a mechanism closely linked to apoptosis [78]. Reciprocally, oxidative stress induces intracellular accumulation of Aβ through enhancing the amyloidogenic pathway [79]. H2O2 is a well-known uncoupler of the mitochondrial respiratory activity, producing a concentration-dependent inhibition of state 3 (ADP-stimulated) respiration and reducing substantially the ADP : O ratio [80]. An evaluation of electron transport chain complexes and Krebs cycle enzymes revealed that alpha-ketoglutarate dehydrogenase, succinate dehydrogenase, and aconitase are susceptible to inactivation, which is a reversible process [81]. Melatonin directly detoxifies H2O2 with the resulting product being N1-acetyl-N2-formyl-5-methoxykynuramine which is also an efficient free radical scavenger [81, 82]. For this reason H2O2 was selected as positive control and the RCR as well as the hydrolytic activity of ATPase in H2O2-injected brains responded favorably to melatonin treatment, which implies that oxidative stress may explain those alterations. However, in fAβ-injected brains, melatonin had a favorable influence on the RCR, but it failed to modulate the ATPase hydrolytic activity. This finding explains the energy hypometabolism linked to Aβ, since ATPase hydrolytic activity is responsible for generating a proton gradient at the expense of ATP. Interestingly, Aβ is similar in structure to the ATP synthase-binding sequence of the inhibitor of F1 (IF1), a naturally occurring inhibitor of the ATPase activity of the F1Fo-ATP synthase complex in mitochondria. Thus, as with IF1, Aβ may inhibit ATPase activity presumably by interacting with the alpha subunit of the F1Fo-ATP synthase complex [83]. We speculate that this direct interaction could cause the failure of the antioxidant therapy to restore the ATPase hydrolytic activity in fAβ-injected brains. Even though melatonin has been demonstrated to improve mitochondrial function in both normal and pathological conditions, this effect is related to its antioxidant activity.

Melatonin did not seem to have a direct effect on the ATPase hydrolytic activity. However, this endogenous neurohormone incorporates into mitochondria and may decrease oxygen consumption concomitantly with its concentration, inhibiting any increase in oxygen flux in the presence of an excess of ADP, and reducing the membrane potential, changes that inhibit the production of and H2O2, as demonstrated in mouse liver cells [84]. Moreover, by using melatonin it is possible to maintain the efficiency of oxidative phosphorylation and ATP synthesis, while increasing the activity of the respiratory complexes (mainly complexes I, III, and IV) [84]. Melatonin also has proven to be effective in preventing mitochondrial nitric oxide synthase induction in parkinsonian mice [85]. However, melatonin also failed to restore the nitrosative stress-induced failure in the ATPase hydrolytic activity in septic mice [86]. These data suggest that Aβ-induced mitochondrial alterations, as those described at early stages in AD before the appearance of amyloid plaques, are the result of internalization of Aβ. Later, continuous overproduction of amyloid peptide, which induces more oxidative stress [44] and neuroinflammation [55, 87], results in extracellular plaque formation. Thus, the effects of Aβ on mitochondria could be an extension of the amyloid cascade. The results presented here support the hypothesis of the internalization of Aβ as a major cause of mitochondrial dysfunction during AD.

Concluding Remarks
Extracellular deposits of Aβ may access mitochondria because of the Aβ ability to permeabilize cellular membranes and lipid bilayers. Thus, Aβ can pass through the membranes from outside in the extracellular space, where these deposits become so huge they form plaques, visible with conventional microscopy. The role of Aβ-induced membrane damage and the ability of Aβ to pass through different compartments are fundamental to understand the mitochondrial energetic failure. All the above mentioned, in a context where lipids and associated oxidative stress play a key role.

4. Materials and Methods

4.1. In Vivo Aβ-Injected Model

Surgical and animal care procedures were performed with strict adherence to the guide for the care and use of laboratory animals (National Institutes of Health, publication number 86–23, Bethesda, MD, USA). All protocols and procedures were approved by the institution’s Animal Care and Use Committee. Male Wistar rats (250–280 grams; 3-month-old) were housed in pairs in a colony room on a 12:12 dark/light cycle with lights off at 20:00 h; food and water were provided ad libitum. The rats were divided ( ) in the following groups: (1) vehicle (PBS) injected rats, (2) fibrillar -injected rats (fAβ), and (3) H2O2 (200 μM) intracerebrally injected rats (H2O2). Two additional groups, fAβ + Mel and H2O2 + Mel were included. In this case, fAβ or H2O2-intracerebrally injected animals received antioxidant treatment with melatonin (Sigma, St. Louis, MO, USA), which was dissolved in the watering vessel at a dose of 20 mg/kg/day [24]. H2O2 was used as a positive control because of its powerful oxidizing capacity and its particular ability to alter mitochondria state 3 NADH-linked respiration [88]. The utility of vehicle solutions as controls against Aβ, such as saline solution or PBS has been well established from published data [89, 90]. Aβ exhibits a chemistry that facilitates the formation of reactive free radical peptides. It is acceptable to use PBS instead of Aβ peptides because even non-toxic Aβ derivatives, not excluding the scrambled Aβ, a usual control in this in vivo model, possess alkylsulfides which may react with oxygen in a metal-independent manner to produce a sulfoxide [91]. Also, these derivatives may generate PBN adducts, indicating the presence of peptide-derived free radical species [72].

Hippocampal injections of Aβ1–42 (2 microliters at a final concentration of 1 mM) were performed as previously described [10, 24, 71]. Lyophilized synthetic Aβ1–42 (Sigma, St. Louis, MO, USA) peptide was solubilized (10−4 M) in filtered, sterile PBS, then was allowed to incubate with continuous agitation (Teflon stir bar at 800 rpm) at 23°C for 36 h [71, 92] in order to form fibrillar aggregates. Rats, anaesthetized with chloral hydrate (350 mg/kg, i.p.), were placed in a stereotaxic instrument for the intracerebral injections over a 5 min period (coordinate: anterior-posterior = −3.8 mm, medial-lateral = 2.0 mm, dorsal-ventral = 2.6 mm from bregma [93], using 5-microliter Hamilton microsyringe coupled with a 30 gauge needle through flexible tubing. The needle was left in place for 5 min after injection. The same coordinates were used for PBS-injected controls and the H2O2 experimental group.

36 hours after the injections, rats were deeply anesthetized and transcardially perfused with 200 mL of PBS. Those animals used for immunohistochemical procedures were additionally perfused with 4% paraformaldehyde. Brain was removed and a piece of tissue (164–180 mg), including the lesioned area, was taken with a punch (diameter 10 mm), at the base of the needle tract. This piece included the hippocampal tissue and adjacent cortical areas.

4.2. Immunohistochemistry

For Aβ immunohistochemistry, 5 mm brain slices were postfixed with paraformaldehyde for 2 hr, washed in PBS, and cut into 25–30 μm thick sections with a Vibratome (Leica). Immunohistochemical staining was carried out using a routine immunoperoxidase technique on free-floating sections. Tissue was first washed in 0.05 M PBS, then rinsed in 1% H2O2 in PBS, washed in 0.05 M PBS, and preincubated in PBS containing 0.3% Triton X-100 (PBST); sections were then incubated overnight at room temperature with rabbit anti-Aβ antiserum (anti-βA42, 1 : 1500, from Santa Cruz) in 0.1% PBST. After 15 h, tissue was washed twice in 0.3% PBST followed by incubation with a horseradish peroxidase-bound goat anti-rabbit IgG secondary antibody for 2 hours (Santa Cruz Biotechnology, Inc.). The tissue was washed in 0.3% PBST, then in PBS, and then reacted with 3,3′-diaminobenzidine (DAB) (Sigma Chemical Company).

For the immunoelectron microscopy, hippocampus tissue samples were fixed in 4% paraformaldehyde for 24 hours and immersed in sucrose in 2.3 M for 24 hours. Small blocks were cut and postfixed in osmium tetroxide 2% in PB 0.2 M for 45 minutes, then embedded for 48 hours in Embed 812 (Electron Microscopy Sciences). Ultrathin sections of 70–90 nm were cut with an ultramicrotome (Reichert Om3) and mounted on nickel grids, then incubated for 2 hours in 5% BSA and 0.1% fish gelatin. For immunolabeling experiment, the mounted sections were then incubated for 24 hours at 4°C with the primary polyclonal antibody Anti-Aβ (Santa Cruz Biotechnology) at dilution 1 : 1000 and then washed four times with PBS 0.1 M and 0.1% tween-20, and further incubated for 3 hours at room temperature with a 6 nm gold-conjugated secondary goat anti-rabbit antibody (Jackson Immunoresearch Laboratories) at dilution 1 : 500. After four washes with PBS, sections were counterstained with 2% uranyl acetate for 15 minutes and lead citrate for 5 minutes and examined in a Zeiss EM 906 transmission electron microscope (Oberkochen, Germany).

4.3. Diet

In order to underline the importance of cholesterol in the neuronal Aβ-induced damage, animals intracerebrally injected with fAβ were divided in two groups, one receive regular Laboratory Rodent Diet chows, while the other group was fed with 4% cholesterol-enriched chows plus 1% colic acid (Harlan Teklan TD. 01418). Images were analyzed by using Image Pro-Plus software (v5.1) and structural damages were determined as a percentage of the damaged membranes against complete, healthy mitochondrial membranes per field.

4.4. Analysis of Mitochondrial Free Radical Generation

Mitotracker red CM-H2XRos (Molecular Probes), a rosamine derivative used to detect mitochondrial free radicals, was diluted in DMSO to form a 1 mM stock solution. 100 μL of that solution were diluted in 5 mL of saline physiological solution and stored sterile at 4°C as working solution. Applied at a dose of 0.030 μg/kg, CM-H2XRos did not affect the functional properties of mitochondria after loading, since neither respiratory output nor cell viability was significant changed, as evaluated in a separate study (data not shown). Two hours following the intraperitoneal injection of CM-H2XRos, animals were perfused transcardially with PBS followed by 4% paraformaldehyde. The brains were immediately removed and immersed in the fixative for 8–10 h. Following a brief washing in PBS, brain slices were cut into 25–30 μm thick sections, including the area of interest, with the vibratome and incubated free-floating in MitoTracker Green (Molecular Probes, Ex/Em 490/516 nm), which selectively stains mitochondria both in live cells and in cells that have been fixed [94]. Then sections were mounted on adhesive (Vecta Bond)-coated glass slides, with a DNA dye, 4′,6-diamidino-2-phenylindole (DAPI), containing mounting medium (Vectashield, Vector Laboratories) in order to evaluate mitochondrial mass in cells with nuclear counterstaining in blue (Ex/Em 359/461 nm). The mitochondrial free radicals were analyzed by monitoring the oxidized fluorescence product (Ex/Em 554/576 nm) of CMH2XRos under a fluorescence microscope (Carl Zeiss Axioskop). Integrated optical density (IOD), number of mitochondria, as well as its mitochondrial area was determined by using image analysis software (Image-Pro Plus v5.1).

4.5. Mitochondrial Isolation

Briefly, brain tissue was minced and placed in prechilled Dounce homogenizer with SHE buffer (0.25 M sucrose, 5 mM HEPES and 1 mM EGTA, PH 7.4), followed by centrifugation at 2500 rpm for 10 min, 4°C, recentrifugation of the supernatant (8500 rpm, 10 min) obtain a crude mitochondrial pellet, which in turn, following a 10 min incubation in ice, was resuspended again in SHE plus delipidized bovine serum albumin (Sigma Chemical Company). Albumin was eliminated by centrifugation of the mitochondrial suspension at 9500 rpm, 10 min. The protein content in the mitochondrial fraction was determined using the Lowry method [95].

4.6. Respiratory Control Ratios (RCRs)

The measurement of oxygen consumption ratios was performed at 34°C using an incubation chamber with a water jacket and a Clark-type O2 electrode (Yellow Spring Instrument Co., Yellow Spring, OH, USA) and the respiratory control ratios calculated according to Chance and Williams [96]. 1.9 mL of air-saturated KME buffer (125 mM KCl, 20 mM MOPS, 5 mM MgCl and 0.1 mM EGTA at pH 7.6) was added to the chamber and equilibrated with the oxygen electrode for 3 min with stirring. Freshly prepared mitochondria (1 mg protein/mL) were then added to the buffer in the chamber and incubated for another 3 min with stirring. Respiration was started by adding 5 mM orthophosphate (Pi), 5 mM succinate and 1 mM ADP. For oxidation of succinate, small amounts of ADP stimulated respiratory ratios (State 3) until ADP became exhausted (State 4). The respiratory control ratio (RCR) was calculated from the ratio of state 3/state 4 oxygen consumption ratios.

4.7. ATPase Hydrolytic Activity

ATPase activity was measured at 40°C in a medium (1 mL) containing 125 mm KCl, 40 mM MOPS (pH = 8), 3 mM MgCl2, plus 0.1 mg of mitochondrial protein, and the reaction was initiated with 40 μL of ATP (75 mM) and 10 minutes later stopped with 30% trichloroacetic acid. Free orthophosphate (Pi) delivered from ATP hydrolysis was measured by a colorimetric assay at 660 nm based on the formation of a phosphomolybdate complex in an acid medium (after the addition of 3.3% ammonium molybdate in 3.8 N H2SO4 and 10% FeSO4) followed by a reduction or complexation with basic dyes that yield colored complexes [97, 98].

4.8. Fluidity Changes of Mitochondrial Membranes

1,3-dipyrenylpropane (DPP) incorporation into membranes forms intramolecular excimers depending mainly on the medium microviscosity and temperature of determination [99]. Membrane fluidity is determined by estimating the excimer to monomer fluorescence intensity ratio (Ie/Im) of this fluorescent probe, a quotient that reflexes the lateral mobility of membrane phospholipids [100]. Briefly, mitochondria were resuspended in Tris-HCl buffer (50 mM, pH 8) and then fragmented by sonication for 15 seconds before being separated by centrifugation at 13000 rpm. The mitochondrial membrane pellet was resuspended and proteins were measured using the Lowry method [95]. 0.1 mg of mitochondrial proteins was mixed in a spectrofluorometric cell containing Tris-HCl (20 mM, pH 7.5). DPP solution in ethanol of spectroscopic grade was diluted (0.02 mg/mL) and mixed with membranes given a molar ratio of fluorescent probe to membrane phospholipids of 1 : 1400 and the mixtures were incubated in the darkness for 4 hours at room temperature. Fluorescence of DPP incorporated into membranes was measured at 24°C on a Perkin Elmer fluorescence spectrometer, LS50B. The fluorophore was excited at 329 nm and the monomer and excimer fluorescence intensities were read at 379 and 480 nm, respectively.

4.9. Statistical Analysis

All data are shown as means ± SE of triplicate experiments. Statistical analysis of the data for multiple comparisons was performed by two-way ANOVA followed by Student’s -tests. For a single comparison, the significance of any differences between means was determined by unpaired -tests. The criterion for significance was in all statistical evaluations.


  1. M. R. D'Andrea, R. G. Nagele, H. Y. Wang, and D. H. S. Lee, “Consistent immunohistochemical detection of intracellular β-Amyloid42 in pyramidal neurons of Alzheimer's disease entorhinal cortex,” Neuroscience Letters, vol. 333, no. 3, pp. 163–166, 2002. View at: Publisher Site | Google Scholar
  2. L. Saavedra, A. Mohamed, V. Ma, S. Kar, and E. P. De Chaves, “Internalization of β-Amyloid peptide by primary neurons in the absence of apolipoprotein E,” Journal of Biological Chemistry, vol. 282, no. 49, pp. 35722–35732, 2007. View at: Publisher Site | Google Scholar
  3. K. Simons and R. Ehehalt, “Cholesterol, lipid rafts, and disease,” Journal of Clinical Investigation, vol. 110, no. 5, pp. 597–603, 2002. View at: Publisher Site | Google Scholar
  4. M. O. Grimm, H. S. Grimm, A. J. Patzold et al., “Regulation of cholesterol and sphingomyelin metabolism by Amyloid-beta and presenilin,” Nature Cell Biology, vol. 7, no. 11, pp. 1118–1123, 2005. View at: Google Scholar
  5. J. Abad-Rodriguez, M. D. Ledesma, K. Craessaerts et al., “Neuronal membrane cholesterol loss enhances Amyloid peptide generation,” Journal of Cell Biology, vol. 167, no. 5, pp. 953–960, 2004. View at: Publisher Site | Google Scholar
  6. B. Wolozin, W. Kellman, P. Ruosseau, G. G. Celesia, and G. Siegel, “Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme a reductase inhibitors,” Archives of Neurology, vol. 57, no. 10, pp. 1439–1443, 2000. View at: Google Scholar
  7. P. Mecocci, A. Cherubini, M. F. Beal et al., “Altered mitochondrial membrane fluidity in ad brain,” Neuroscience Letters, vol. 207, no. 2, pp. 129–132, 1996. View at: Publisher Site | Google Scholar
  8. R. Resende, P. I. Moreira, T. Proença et al., “Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease,” Free Radical Biology and Medicine, vol. 44, no. 12, pp. 2051–2057, 2008. View at: Publisher Site | Google Scholar
  9. S. Rosales-Corral, D. X. Tan, R. J. Reiter, M. Valdivia-Velázquez, J. P. Acosta-Martínez, and G. G. Ortiz, “Kinetics of the neuroinflammation-oxidative stress correlation in rat brain following the injection of fibrillar Amyloid-β onto the hippocampus in vivo,” Journal of Neuroimmunology, vol. 150, no. 1-2, pp. 20–28, 2004. View at: Publisher Site | Google Scholar
  10. S. M. Yatin, S. Varadarajan, C. D. Link, and D. A. Butterfield, “In vitro and in vivo oxidative stress associated with Alzheimer's Amyloid β-peptide (1–42),” Neurobiology of Aging, vol. 20, no. 3, pp. 325–342, 1999. View at: Publisher Site | Google Scholar
  11. K. C. Silva, M. A. B. Rosales, S. K. Biswas, J. B. L. De Faria, and J. M. L. De Faria, “Diabetic retinal neurodegeneration is associated with mitochondrial oxidative stress and is improved by an angiotensin receptor blocker in a model combining hypertension and diabetes,” Diabetes, vol. 58, no. 6, pp. 1382–1390, 2009. View at: Publisher Site | Google Scholar
  12. K. Tońska, A. Sołyga, and E. Bartnik, “Mitochondria and aging: innocent bystanders or guilty parties?” Journal of Applied Genetics, vol. 50, no. 1, pp. 55–62, 2009. View at: Google Scholar
  13. A. Jana, E. L. Hogan, and K. Pahan, “Ceramide and neurodegeneration: susceptibility of neurons and oligodendrocytes to cell damage and death,” Journal of the Neurological Sciences, vol. 278, no. 1-2, pp. 5–15, 2009. View at: Publisher Site | Google Scholar
  14. M. Michikawa, “Role of cholesterol in Amyloid cascade: cholesterol-dependent modulation of tau phosphorylation and mitochondrial function,” Acta Neurologica Scandinavica, vol. 114, no. 185, pp. 21–26, 2006. View at: Publisher Site | Google Scholar
  15. R. G. Cutler, J. Kelly, K. Storie et al., “Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 7, pp. 2070–2075, 2004. View at: Publisher Site | Google Scholar
  16. S. Mitew, M. T. K. Kirkcaldie, G. M. Halliday, C. E. Shepherd, J. C. Vickers, and T. C. Dickson, “Focal demyelination in Alzheimer's disease and transgenic mouse models,” Acta Neuropathologica, vol. 119, no. 5, pp. 567–577, 2010. View at: Publisher Site | Google Scholar
  17. G. Bartzokis, “Alzheimer's disease as homeostatic responses to age-related myelin breakdown,” Neurobiology of Aging, vol. 32, no. 8, pp. 1341–1371, 2011. View at: Publisher Site | Google Scholar
  18. C. Caspersen, N. Wang, J. Yao et al., “Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease,” The FASEB Journal, vol. 19, no. 14, pp. 2040–2041, 2005. View at: Google Scholar
  19. J. W. Lustbader, M. Cirilli, C. Lin et al., “Abad directly links Aβ to mitochondrial toxicity in Alzheimer's disease,” Science, vol. 304, no. 5669, pp. 448–452, 2004. View at: Publisher Site | Google Scholar
  20. M. Manczak, T. S. Anekonda, E. Henson, B. S. Park, J. Quinn, and P. H. Reddy, “Mitochondria are a direct site of Aβ accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression,” Human Molecular Genetics, vol. 15, no. 9, pp. 1437–1449, 2006. View at: Publisher Site | Google Scholar
  21. C. A. Hansson Petersen, N. Alikhani, H. Behbahani et al., “The Amyloid β-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 35, pp. 13145–13150, 2008. View at: Publisher Site | Google Scholar
  22. D. De Pietri Tonelli, M. Mihailovich, A. Di Cesare, F. Codazzi, F. Grohovaz, and D. Zacchetti, “Translational regulation of BACE-1 expression in neuronal and non-neuronal cells,” Nucleic Acids Research, vol. 32, no. 5, pp. 1808–1817, 2004. View at: Publisher Site | Google Scholar
  23. J. E. Maggio and P. W. Mantyh, “Brain Amyloid—a physicochemical perspective,” Brain Pathology, vol. 6, no. 2, pp. 147–162, 1996. View at: Google Scholar
  24. S. Rosales-Corral, D. X. Tan, R. J. Reiter et al., “Orally administered melatonin reduces oxidative stress and proinflammatory cytokines induced by Amyloid-β peptide in rat brain: a comparative, in vivo study versus vitamin C and E,” Journal of Pineal Research, vol. 35, no. 2, pp. 80–84, 2003. View at: Publisher Site | Google Scholar
  25. S. A. Rosales-Corral, D. Acuna-Castroviejo, A. Coto-Montes et al., “Alzheimer's disease: pathological mechanisms and the beneficial role of melatonin,” Journal of Pineal Research, vol. 52, no. 2, pp. 167–202, 2012. View at: Google Scholar
  26. A. Galano, D. X. Tan, and R. J. Reiter, “Melatonin as a natural ally against oxidative stress: a physicochemical examination,” Journal of Pineal Research, vol. 51, no. 1, pp. 1–16, 2011. View at: Publisher Site | Google Scholar
  27. D. Bonnefont-Rousselot, F. Collin, D. Jore, and M. Gardès-Albert, “Reaction mechanism of melatonin oxidation by reactive oxygen species in vitro,” Journal of Pineal Research, vol. 50, no. 3, pp. 328–335, 2011. View at: Publisher Site | Google Scholar
  28. J. B. Hoppe, R. L. Frozza, A. P. Horn et al., “Amyloid-β neurotoxicity in organotypic culture is attenuated by melatonin: involvement of GSK-3β, tau and neuroinflammation,” Journal of Pineal Research, vol. 48, no. 3, pp. 230–238, 2010. View at: Publisher Site | Google Scholar
  29. W. Dong, F. Huang, W. Fan et al., “Differential effects of melatonin on Amyloid-β peptide 25–35-induced mitochondrial dysfunction in hippocampal neurons at different stages of culture,” Journal of Pineal Research, vol. 48, no. 2, pp. 117–125, 2010. View at: Publisher Site | Google Scholar
  30. S. Cheng, C. Ma, H. Qu, W. Fan, J. Pang, and H. He, “Differential effects of melatonin on hippocampal neurodegeneration in different aged accelerated senescence prone mouse-8,” Neuro Endocrinology Letters, vol. 29, no. 1, pp. 91–99, 2008. View at: Google Scholar
  31. B. Caballero, I. Vega-Naredo, V. Sierra et al., “Favorable effects of a prolonged treatment with melatonin on the level of oxidative damage and neurodegeneration in senescence-accelerated mice,” Journal of Pineal Research, vol. 45, no. 3, pp. 302–311, 2008. View at: Publisher Site | Google Scholar
  32. Y. Hong, K. J. Palaksha, K. Park et al., “Melatonin plus exercise-based neurorehabilitative therapy for spinal cord injury,” Journal of Pineal Research, vol. 49, no. 3, pp. 201–209, 2010. View at: Publisher Site | Google Scholar
  33. A. Espinar, A. García-Oliva, E. M. Isorna, A. Quesada, F. A. Prada, and J. M. Guerrero, “Neuroprotection by melatonin from glutamate-induced excitotoxicity during development of the cerebellum in the chick embryo,” Journal of Pineal Research, vol. 28, no. 2, pp. 81–88, 2000. View at: Publisher Site | Google Scholar
  34. M. J. Jou, T. I. Peng, L. F. Hsu et al., “Visualization of melatonin's multiple mitochondrial levels of protection against mitochondrial Ca2+-mediated permeability transition and beyond in rat brain astrocytes,” Journal of Pineal Research, vol. 48, no. 1, pp. 20–38, 2010. View at: Publisher Site | Google Scholar
  35. G. Paradies, G. Petrosillo, V. Paradies, R. J. Reiter, and F. M. Ruggiero, “Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease,” Journal of Pineal Research, vol. 48, no. 4, pp. 297–310, 2010. View at: Publisher Site | Google Scholar
  36. S. A. Andrabi, I. Sayeed, D. Siemen, G. Wolf, and T. F. Horn, “Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for anti-apoptotic effects of melatonin,” The FASEB Journal, vol. 18, no. 7, pp. 869–871, 2004. View at: Google Scholar
  37. Y. Parman, E. Battaloglu, I. Baris et al., “Clinicopathological and genetic study of early-onset demyelinating neuropathy,” Brain, vol. 127, no. 11, pp. 2540–2550, 2004. View at: Google Scholar
  38. N. G. N. Milton, “Role of hydrogen peroxide in the aetiology of Alzheimer's disease: implications for treatment,” Drugs and Aging, vol. 21, no. 2, pp. 81–100, 2004. View at: Publisher Site | Google Scholar
  39. K. L. Campos, J. Giovanelli, and S. Kaufman, “Characteristics of the nitric oxide synthase-catalyzed conversion of arginine to N-hydroxyarginine, the first oxygenation step in the enzymic synthesis of nitric oxide,” Journal of Biological Chemistry, vol. 270, no. 4, pp. 1721–1728, 1995. View at: Publisher Site | Google Scholar
  40. M. D. Brand and D. G. Nicholls, “Assessing mitochondrial dysfunction in cells,” Biochemical Journal, vol. 435, no. 2, pp. 297–312, 2011. View at: Publisher Site | Google Scholar
  41. C. Chinopoulos, A. A. Gerencser, M. Mandi et al., “Forward operation of adenine nucleotide translocase during F0F1-ATPase reversal: critical role of matrix substrate-level phosphorylation,” The FASEB Journal, vol. 24, no. 7, pp. 2405–2416, 2010. View at: Google Scholar
  42. L. Lecanu, J. Greeson, and V. Papadopoulos, “Beta-Amyloid and oxidative stress jointly induce neuronal death, Amyloid deposits, gliosis, and memory impairment in the rat brain,” Pharmacology, vol. 76, no. 1, pp. 19–33, 2006. View at: Publisher Site | Google Scholar
  43. J. Hardy and D. J. Selkoe, “The Amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics,” Science, vol. 297, no. 5580, pp. 353–356, 2002. View at: Publisher Site | Google Scholar
  44. R. H. Swerdlow and S. M. Khan, “A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease,” Medical Hypotheses, vol. 63, no. 1, pp. 8–20, 2004. View at: Publisher Site | Google Scholar
  45. M. E. Clementi, S. Marini, M. Coletta, F. Orsini, B. Giardina, and F. Misiti, “Aβ(31–35) and Aβ(25–35) fragments of Amyloid beta-protein induce cellular death through apoptotic signals: role of the redox state of methionine-35,” The FEBS Letters, vol. 579, no. 13, pp. 2913–2918, 2005. View at: Publisher Site | Google Scholar
  46. X. Gao, C. Y. Zheng, L. Yang, X. C. Tang, and H. Y. Zhang, “Huperzine a protects isolated rat brain mitochondria against β-Amyloid peptide,” Free Radical Biology and Medicine, vol. 46, no. 11, pp. 1454–1462, 2009. View at: Publisher Site | Google Scholar
  47. G. Aliev, D. Seyidova, B. T. Lamb et al., “Mitochondria and vascular lesions as a central target for the development of Alzheimer's disease and Alzheimer disease-like pathology in transgenic mice,” Neurological Research, vol. 25, no. 6, pp. 665–674, 2003. View at: Publisher Site | Google Scholar
  48. G. Alvarez, M. Ramos, F. Ruiz, J. Satrustegui, and E. Bogonez, “Pyruvate protection against beta-Amyloid-induced neuronal death: role of mitochondrial redox state,” Journal of Neuroscience Research, vol. 73, no. 2, pp. 260–269, 2003. View at: Google Scholar
  49. Y. H. Chen, Y. X. Liang, L. Q. Chen et al., “Nephrotoxicity of tacrolimus and preventive effect of diltiazem: experiment with rats,” National Medical Journal of China, vol. 89, no. 10, pp. 704–708, 2009. View at: Publisher Site | Google Scholar
  50. H. Lin, R. Bhatia, and R. Lal, “Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology,” The FASEB Journal, vol. 15, no. 13, pp. 2433–2444, 2001. View at: Google Scholar
  51. L. Canevari, J. B. Clark, and T. E. Bates, “Beta-Amyloid fragment 25–35 selectively decreases complex IV activity in isolated mitochondria,” The FEBS Letters, vol. 457, no. 1, pp. 131–134, 1999. View at: Publisher Site | Google Scholar
  52. J. K. Parks, T. S. Smith, P. A. Trimmer, J. P. Bennett Jr., and W. Davis Parker Jr., “Neurotoxic Aβ peptides increase oxidative stress in vivo through nmda-receptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro,” Journal of Neurochemistry, vol. 76, no. 4, pp. 1050–1056, 2001. View at: Publisher Site | Google Scholar
  53. J. J. Liang, E. T. Kimchi, K. F. Staveley-O'Carroll, and D. Tan, “Diagnostic and prognostic biomarkers in pancreatic carcinoma,” International Journal of Clinical and Experimental Pathology, vol. 2, no. 1, pp. 1–10, 2009. View at: Google Scholar
  54. B. F. Liu, S. Song, M. Hanson, and J. J. N. Liang, “Protein-protein interactions involving congenital cataract T5P γC-crystallin mutant: a confocal fluorescence microscopy study,” Experimental Eye Research, vol. 87, no. 6, pp. 515–520, 2008. View at: Publisher Site | Google Scholar
  55. S. Rosales-Corral, R. J. Reiter, D. X. Tan, G. G. Ortiz, and G. Lopez-Armas, “Functional aspects of redox control during neuroinflammation,” Antioxidants and Redox Signaling, vol. 13, no. 2, pp. 193–247, 2010. View at: Publisher Site | Google Scholar
  56. J. Yao, R. W. Irwin, L. Zhao, J. Nilsen, R. T. Hamilton, and R. D. Brinton, “Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 34, pp. 14670–14675, 2009. View at: Publisher Site | Google Scholar
  57. B. F. Liu and J. J. N. Liang, “Interaction and biophysical properties of human lens Q155βB2-crystallin mutant,” Molecular Vision, vol. 11, pp. 321–327, 2005. View at: Google Scholar
  58. P. L. Dentuto, L. Catucci, P. Cosma et al., “Effect of cyclodextrins on the physicochemical properties of chlorophyll a in aqueous solution,” Journal of Physical Chemistry B, vol. 109, no. 3, pp. 1313–1317, 2005. View at: Publisher Site | Google Scholar
  59. W. A. Pryor, K. N. Houk, C. S. Foote et al., “Free radical biology and medicine: it's a gas, man!,” American Journal of Physiology, vol. 291, no. 3, pp. R491–R511, 2006. View at: Publisher Site | Google Scholar
  60. J. E. B. McCallum, C. Y. Kuniyoshi, and C. S. Foote, “Characterization of 5-hydroxy-8-oxo-7,8-dihydroguanosine in the photosensitized oxidation of 8-oxo-7,8-dihydroguanosine and its rearrangement to spiroiminodihydantoin,” Journal of the American Chemical Society, vol. 126, no. 51, pp. 16777–16782, 2004. View at: Publisher Site | Google Scholar
  61. S. R. Ji, Y. Wu, and S. F. Sui, “Cholesterol is an important factor affecting the membrane insertion of β-Amyloid peptide (Aβ1–40), which may potentially inhibit the fibril formation,” Journal of Biological Chemistry, vol. 277, no. 8, pp. 6273–6279, 2002. View at: Publisher Site | Google Scholar
  62. L. P. Choo-Smith, W. Garzon-Rodriguez, C. G. Glabe, and W. K. Surewicz, “Acceleration of Amyloid fibril formation by specific binding of Aβ-(1–40) peptide to ganglioside-containing membrane vesicles,” Journal of Biological Chemistry, vol. 272, no. 37, pp. 22987–22990, 1997. View at: Publisher Site | Google Scholar
  63. H. L. Smith, M. C. Howland, A. W. Szmodis et al., “Early stages of oxidative stress-induced membrane permeabilization: a neutron reflectometry study,” Journal of the American Chemical Society, vol. 131, no. 10, pp. 3631–3638, 2009. View at: Publisher Site | Google Scholar
  64. A. Miyamoto, T. Araiso, T. Koyama, and H. Ohshika, “Membrane viscosity correlates with α1-adrenergic signal transduction of the aged rat cerebral cortex,” Journal of Neurochemistry, vol. 55, no. 1, pp. 70–75, 1990. View at: Publisher Site | Google Scholar
  65. G. H. López, M. G. I. De Boschero, P. I. Castagnet, and N. M. Giusto, “Age-associated changes in the content and fatty acid composition of brain glycerophospholipids,” Comparative Biochemistry and Physiology, vol. 112, no. 2, pp. 331–343, 1995. View at: Publisher Site | Google Scholar
  66. D. Burdick, J. Kosmoski, M. F. Knauer, and C. G. Glabe, “Preferential adsorption, internalization and resistance to degradation of the major isoform of the Alzheimer's Amyloid peptide, a β1–42, in differentiated PC12 cells,” Brain Research, vol. 746, no. 1-2, pp. 275–284, 1997. View at: Publisher Site | Google Scholar
  67. P. M. Clifford, S. Zarrabi, G. Siu et al., “Aβ peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons,” Brain Research, vol. 1142, no. 1, pp. 223–236, 2007. View at: Publisher Site | Google Scholar
  68. A. E. Roher, N. Weiss, T. A. Kokjohn et al., “Increased Aβ peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease,” Biochemistry, vol. 41, no. 37, pp. 11080–11090, 2002. View at: Publisher Site | Google Scholar
  69. G. Bartzokis, P. H. Lu, and J. Mintz, “Human brain myelination and Amyloid beta deposition in Alzheimer's disease,” Alzheimer's and Dementia, vol. 3, no. 2, pp. 122–125, 2007. View at: Publisher Site | Google Scholar
  70. G. Bartzokis, P. H. Lu, D. H. Geschwind et al., “Apolipoprotein e affects both myelin breakdown and cognition: implications for age-related trajectories of decline into dementia,” Biological Psychiatry, vol. 62, no. 12, pp. 1380–1387, 2007. View at: Publisher Site | Google Scholar
  71. D. T. Weldon, S. D. Rogers, J. R. Ghilardi et al., “Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo,” The Journal of Neuroscience, vol. 18, no. 6, pp. 2161–2173, 1998. View at: Google Scholar
  72. K. Hensley, J. M. Carney, M. P. Mattson et al., “A model for β-Amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 8, pp. 3270–3274, 1994. View at: Google Scholar
  73. S. Sharma, J. Prasanthi, E. Schommer, G. Feist, and O. Ghribi, “Hypercholesterolemia-induced Aβ accumulation in rabbit brain is associated with alteration in IGF-1 signaling,” Neurobiology of Disease, vol. 32, no. 3, pp. 426–432, 2008. View at: Publisher Site | Google Scholar
  74. A. Papassotiropoulos, D. Lütjohann, M. Bagli et al., “Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease,” Neuroreport, vol. 11, no. 9, pp. 1959–1962, 2000. View at: Google Scholar
  75. Y. M. Kuo, M. R. Emmerling, C. L. Bisgaier et al., “Elevated low-density lipoprotein in Alzheimer's disease correlates with brain Aβ 1–42 levels,” Biochemical and Biophysical Research Communications, vol. 252, no. 3, pp. 711–715, 1998. View at: Publisher Site | Google Scholar
  76. P. B. Shelat, M. Chalimoniuk, J. H. Wang et al., “Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons,” Journal of Neurochemistry, vol. 106, no. 1, pp. 45–55, 2008. View at: Publisher Site | Google Scholar
  77. H. Y. Yoon, S. H. Lee, S. W. Cho et al., “TAT-mediated delivery of human glutamate dehydrogenase into PC12 cells,” Neurochemistry International, vol. 41, no. 1, pp. 37–42, 2002. View at: Publisher Site | Google Scholar
  78. M. J. Hsu, J. R. Sheu, C. H. Lin, M. Y. Shen, and C. Y. Hsu, “Mitochondrial mechanisms in Amyloid beta peptide-induced cerebrovascular degeneration,” Biochimica et Biophysica Acta, vol. 1800, no. 3, pp. 290–296, 2010. View at: Publisher Site | Google Scholar
  79. H. Misonou, M. Morishima-Kawashima, and Y. Ihara, “Oxidative stress induces intracellular accumulation of Amyloid β- protein (Aβ) in human neuroblastoma cells,” Biochemistry, vol. 39, no. 23, pp. 6951–6959, 2000. View at: Publisher Site | Google Scholar
  80. N. R. Sims, M. F. Anderson, L. M. Hobbs et al., “Impairment of brain mitochondrial function by hydrogen peroxide,” Molecular Brain Research, vol. 77, no. 2, pp. 176–184, 2000. View at: Publisher Site | Google Scholar
  81. R. J. Reiter, D. X. Tan, L. C. Manchester, and M. R. El-Sawi, “Melatonin reduces oxidant damage and promotes mitochondrial respiration: implications for aging,” Annals of the New York Academy of Sciences, vol. 959, pp. 238–250, 2002. View at: Google Scholar
  82. D. X. Tan, L. C. Manchester, S. Burkhardt et al., “N1-acetyl-N2-formyl-5-methoxykynuramine, a biogenic amine and melatonin metabolite, functions as a potent antioxidant,” The FASEB Journal, vol. 15, no. 12, pp. 2294–2296, 2001. View at: Google Scholar
  83. C. Schmidt, E. Lepsverdize, S. L. Chi et al., “Amyloid precursor protein and Amyloid β-peptide bind to ATP synthase and regulate its activity at the surface of neural cells,” Molecular Psychiatry, vol. 13, no. 10, pp. 953–969, 2008. View at: Publisher Site | Google Scholar
  84. A. Lopez, J. A. Garcia, G. Escames et al., “Melatonin protects the mitochondria from oxidative damage reducing oxygen consumption, membrane potential, and superoxide anion production,” Journal of Pineal Research, vol. 46, no. 2, pp. 188–198, 2009. View at: Google Scholar
  85. V. Tapias, G. Escames, L.C. Lopez et al., “Melatonin and its brain metabolite N1-acetyl-5-methoxykynuramine prevent mitochondrial nitric oxide synthase induction in parkinsonian mice,” Journal of Neuroscience Research, vol. 87, no. 13, pp. 3002–3010, 2009. View at: Google Scholar
  86. L. C. Lopez, G. Escames, F. Ortiz, E. Ros, and D. Acuna-Castroviejo, “Melatonin restores the mitochondrial production of ATP in septic mice,” Neuro Endocrinology Letters, vol. 27, no. 5, pp. 623–630, 2006. View at: Google Scholar
  87. J. W. Lee, Y. K. Lee, D. Y. Yuk et al., “Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-Amyloid generation,” Journal of Neuroinflammation, vol. 5, article 37, 2008. View at: Publisher Site | Google Scholar
  88. A. C. Nulton-Persson and L. I. Szweda, “Modulation of mitochondrial function by hydrogen peroxide,” Journal of Biological Chemistry, vol. 276, no. 26, pp. 23357–23361, 2001. View at: Publisher Site | Google Scholar
  89. A. Gonzalo-Ruiz, J. M. Sanz, J. Arévalo, C. Geula, and P. Gonzalo, “Amyloid beta peptide-induced cholinergic fibres loss in the cerebral cortex of the rat is modified by diet high in lipids and by age,” Journal of Chemical Neuroanatomy, vol. 29, no. 1, pp. 31–48, 2005. View at: Publisher Site | Google Scholar
  90. L. Giovannelli, F. Casamenti, C. Scali, L. Bartolini, and G. Pepeu, “Differential effects of Amyloid peptides β-(1–40) and β-(25–35) injections into the rat nucleus basalis,” Neuroscience, vol. 66, no. 4, pp. 781–792, 1995. View at: Publisher Site | Google Scholar
  91. J. J. Liang, C. L. Gu, M. L. Kacher, and C. S. Foote, “Chemistry of singlet oxygen. 45. Mechanism of the photooxidation of sulfides,” Journal of the American Chemical Society, vol. 105, no. 14, pp. 4717–4721, 1983. View at: Google Scholar
  92. K. Ishii, K. Nunoki, H. Murakoshi, and N. Taira, “Cloning and modulation by endothelin-1 of rat cardiac K channel,” Biochemical and Biophysical Research Communications, vol. 184, no. 3, pp. 1484–1489, 1992. View at: Publisher Site | Google Scholar
  93. G. Paxinos, The Rat Nervous System, Academic Press, Sydney, Australia, 4th edition, 1984.
  94. A. Qazi, M.W. Halterman, Z. Mi, T. Zhang, and N.F. Schor, “Chopper is prodeath regardless of the effect of p75ICD on sensitivity to oxidative stress,” Oxidative Medicine and Cellular Longevity, vol. 2011, Article ID 391659, 8 pages, 2011. View at: Publisher Site | Google Scholar
  95. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, “Protein measurement with the folin phenol reagent,” The Journal of Biological Chemistry, vol. 193, no. 1, pp. 265–275, 1951. View at: Google Scholar
  96. B. Chance and G. R. Williams, “The respiratory chain and oxidative phosphorylation,” Advances in Enzymology and Related Subjects of Biochemistry, vol. 17, pp. 65–134, 1956. View at: Google Scholar
  97. R. Sacco, A. Giovanelli, L. Giuliano et al., “Epidemiological behaviour of perforated peptic ulcer before and after the introduction of antisecretory medical therapy. personal experience,” Minerva Chirurgica, vol. 50, no. 10, pp. 871–878, 1995. View at: Google Scholar
  98. F. Evangelisti, A. Baroncelli, P. Bonasoni, G. Giovanelli, and F. Ravegnani, “Differential optical absorption spectrometer for measurement of tropospheric pollutants,” Applied Optics, vol. 34, no. 15, pp. 2737–2744, 1995. View at: Google Scholar
  99. R. Mejia, M.C. Gomez-Eichelmann, and M.S. Fernandez, “Escherichia coli membrane fluidity as detected by excimerization of dipyrenylpropane: sensitivity to the bacterial fatty acid profile,” Archives of Biochemistry and Biophysics, vol. 368, no. 1, pp. 156–160, 1999. View at: Google Scholar
  100. H. J. Galla, W. Hartmann, U. Theilen, and E. Sackmann, “On two-dimensional passive random walk in lipid bilayers and fluid pathways in biomembranes,” Journal of Membrane Biology, vol. 48, no. 3, pp. 215–236, 1979. View at: Google Scholar

Copyright © 2012 Sergio Rosales-Corral et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.